Fused ring compounds
AssigneeGenentech, Inc.
InventorsSushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
Life of this patent
Estimating the term…
Abstract
This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
Claims40
A compound of Formula (II):
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R2 is NH2;
- R3 is H;
- R4 is H or C1-6 alkyl;
- R5 is CF3,
- R7 is selected from the group consisting of H, cyano, and halo;
- R8 and R9 are each independently selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, C1-6 hydroxyalkyl, cyano, and halo;
- wherein C1-6 alkyl is optionally substituted with one substituent selected from the group consisting of:
- methanesulfonyl (mesyl), p-toluenesulfonyl (tosyl), an alkyl or aryl sulfonate leaving group, C1-6 alkanoylamino, C1-6 alkoxy, C1-6 alkylamino, C1-6 alkylsulfonylamino, C6-12 dialkylamino, and C1-6 haloalkoxy;
- or
- R7 and R8 together form a triple bond between the carbons to which they are attached, or R7 and R8 together with the carbons to which they are each bonded form a C3-7 cycloalkenyl optionally substituted with one or two halo substituents;
- and R9 is selected from the group consisting of H, C1-6 alkyl, C1-6 haloalkyl, cyano, and halo;
- wherein C1-6 alkyl is optionally substituted with one substituent selected from the group consisting of:
- C1-6 alkanoylamino, C1-6 alkoxy, C1-6 alkylamino, C1-6 alkylsulfonylamino, C6-12 dialkylamino, and C1-6 haloalkoxy;
- X is a 4- to 7-membered heterocyclyl, which is optionally substituted with 1 to 4 substituents, wherein each substituent is independently selected from the group consisting of cyano, C1-6 alkyl, C1-6 cyanoalkyl, and C1-6 haloalkyl;
- Y is -L-Y1;
- Y1 is selected from the group consisting of C1-6 alkyl substituted with a 4- to 10-membered heterocyclyl that is optionally substituted with 1-4 Y1a substituents, C1-6 alkyl substituted with a C1-6 dialkylamino substituent, C1-6 alkyl substituted with a C1-6 dialkylamino cyclopropyl, C3-7 cycloalkyl substituted with a C1-6 dialkylamino, and 4- to 10-membered heterocyclyl substituted with methyl;
- each Y1a is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 alkoxy, 3- to 7-membered heterocyclyl, C1-6 alkoxyC1-6alkyl, C1-6 haloalkyl, oxo, hydroxy, NH2, cyano, C1-6 carboxyalkyl, C1-6 cyanoalkyl, C1-6 hydroxyalkyl, and C1-6 haloalkoxy;
- L is O;
- U is C(R6a);
- V is C(R6b);
- W is C(R6c) or N;
- each of R6a, R6b, and R6c are independently selected from the group consisting of H, OH, NH2, halo, cyano, carbamoyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 alkyl, C1-6 alkyl substituted with a 4- to 10-membered heterocyclyl substituent, C1-6 alkylsulfanyl, C1-6 alkylsulfonyl, C1-6 alkylthio, C1-6 haloalkylthio, C2-6 alkynyl, C1-6 alkylamino, C6-14 aryl, C1-6 aminoalkyl, C1-6 carbamoylalkyl, C1-6 carboxyalkyl, C1-6 cyanoalkyl, C3-7 cycloalkyl, C1-6 haloalkoxy, C1-6 haloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocyclyl;
- and
- n is selected from the group consisting of 0, 1, and 2.
A compound of Formula (III):
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R2 is NH2;
- R3 is H C1-6 alkyl;
- R4 is H or C1-6 alkyl;
- R5 is CF3;
- R10 is selected from the group consisting of R10a and —C(O)—R10a;
- R10a is selected from the group consisting of oxiranyl and aziridinyl;
- X is a 4- to 7-membered heterocyclyl which is optionally substituted with 1 to 4 substituents, wherein each substituent is independently selected from the group consisting of cyano, C1-6 alkyl, C1-6 cyanoalkyl, and C1-6 haloalkyl;
- Y is selected from the group consisting of -L-Y1;
- Y1 dis selected from the group consisting of C1-6 alkyl substituted with a 4- to 10-membered heterocyclyl that is optionally substituted with 1-4 Y1a substituents, C1-6 alkyl substituted with a C1-6 dialkylamino substituent, C1-6 alkyl substituted with a C1-6 dialkylamino cyclopropyl, C3-7 cycloalkyl substituted with a C1-6 dialkylamino, and a 4- to 10-membered heterocyclyl substituted with methyl;
- each Y1a is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 alkoxy, 3- to 7-membered heterocyclyl, C1-6 alkoxyC1-6 alkyl, C1-6 haloalkyl, oxo, hydroxy, NH2, cyano, C1-6 carboxyalkyl, C1-6 cyanoalkyl, C1-6 hydroxyalkyl, and C1-6 haloalkoxy;
- L is O;
- U is C(R6a);
- V is C(R6b);
- W is C(R6c) or N;
- each of R6a, R6b, and R6c are independently selected from the group consisting of H, OH, NH2, halo, cyano, carbamoyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 alkyl, C1-6 alkyl substituted with a 4- to 10-membered heterocyclyl substituent, C1-6 alkylsulfanyl, C1-6 alkylsulfonyl, C1-6 alkylthio, C1-6 haloalkylthio, C2-6 alkynyl, C1-6 alkylamino, C6-14 aryl, C1-6 aminoalkyl, C1-6 carbamoylalkyl, C1-6 carboxyalkyl, C1-6 cyanoalkyl, C3-7 cycloalkyl, C1-6 haloalkoxy, C1-6 haloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocyclyl;
- and
- n is selected from the group consisting of 0, 1, and 2.
A compound of Formula (IV):
- or a pharmaceutically acceptable salt thereof;
- wherein,
- R1 is selected from the group consisting of:
- R12 is selected from the group consisting of C1-6 alkanoyl, C1-6 alkyl, and C1-6 alkylsulfonyl;
- R13 is selected from the group consisting of H, C1-6 alkyl and C1-6 haloalkyl;
- R13a is halo;
- R14 is halo;
- X is a 4- to 7-membered heterocyclyl, which is optionally substituted with 1 to 4 substituents, wherein each substituent is independently selected from the group consisting of cyano, C1-6 alkyl, C1-6 cyanoalkyl, and C1-6 haloalkyl;
- Y is selected from the group consisting of
- U is C(R6a);
- V is C(R6b);
- W is C(R6b) or N;
- each of R6a, R6b, and R6c are independently selected from the group consisting of H, OH, NH2, halo, cyano, carbamoyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 alkyl, C1-6 alkyl substituted with a 4- to 10-membered heterocyclyl substituent, C1-6 alkylsulfanyl, C1-6 alkylsulfonyl, C1-6 alkylthio, C1-6 haloalkylthio, C2-6 alkynyl, C1-6 alkylamino, C6-14 aryl, C1-6 aminoalkyl, C1-6 carbamoylalkyl, C1-6 carboxyalkyl, C1-6 cyanoalkyl, C3-7 cycloalkyl, C1-6 haloalkoxy, C1-6 haloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocyclyl;
- n is selected from the group consisting of 0, 1, and 2;
- and
- R11 is selected from the group consisting of:
A compound having a Formula selected from the group consisting of:
- or a pharmaceutically acceptable salt thereof,
- wherein:
- R2 is NH2;
- R3 is H;
- R4 is H or C1-6 alkyl;
- R5 is CF3;
- Y is of -L-Y1;
- Y1 is selected from the group consisting of C1-6 alkyl, C1-6 alkyl substituted with a 4- to 10-membered heterocyclyl that is optionally substituted with 1-4 Y1a substituents, C1-6 alkyl substituted with a C1-6 dialkylamino substituent, C1-6 alkyl substituted with a C1-6 dialkylamino cyclopropyl C3-7 cycloalkyl substituted with a C1-6 dialkylamino, and 4- to 10-membered heterocyclyl substituted with methyl;
- each Y1a is independently selected from the group consisting of halo, C1-6 alkyl, C1-6 alkoxy, 3- to 7-membered heterocyclyl, C1-6 alkoxyC1-6 alkyl, C1-6 haloalkyl, oxo, hydroxy, NH2, cyano, C1-6 carboxyalkyl, C1-6 cyanoalkyl, C1-6 hydroxyalkyl, and C1-6 haloalkoxy;
- L is O;
- U is C(R6a);
- V is C(R6b);
- W is C(R6c) or N;
- and
- each of R6a, R6b, and R6c are independently selected from the group consisting of H, OH, NH2, halo, cyano, carbamoyl, C2-6 alkenyl, C1-6 alkoxy, C1-6 alkyl, C1-6 alkyl substituted with a 4- to 10-membered heterocyclyl substituent, C1-6 alkylsulfanyl, C1-6 alkylsulfonyl, C1-6 alkylthio, C1-6 haloalkylthio, C2-6 alkynyl, C1-6 alkylamino, C6-14 aryl, C1-6 aminoalkyl, C1-6 carbamoylalkyl, C1-6 carboxyalkyl, C1-6 cyanoalkyl, C3-7 cycloalkyl, C1-6 haloalkoxy, C1-6 haloalkyl, 5- to 10-membered heteroaryl, and 4- to 10-membered heterocyclyl.
A compound having formula:
- or a pharmaceutically acceptable salt thereof.
A compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A compound having the formula:
- or a pharmaceutically acceptable salt thereof.
A compound having the formula;
- or a pharmaceutically acceptable salt thereof.
A compound having the formula:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.